Evidence map›Paper›PMID 33545970›Full record

ArticleMedicine2021

New insights into erythropoietin and erythropoietin receptor in laryngeal cancer tissue.

Jelena Vukelic, Renata Dobrila-Dintinjana, Blazen Marijic, Diana Marzic, Tamara Braut, Marko Velepic

Open access · goldAbstract read
In one paragraph

Article in Medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.7field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Pan-Cancer Analysis Based onFrontiers in oncology · 2022
    Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Jelena VukelicDepartment for Otolaryngology and Head and Neck surgery.
Renata Dobrila-DintinjanaDepartment for radiotherapy and oncology.
Blazen MarijicDepartment for Otolaryngology and Head and Neck surgery.
Diana MarzicCenter for audiology and phoniatry, Clinical Hospital Center Rijeka, Kresimirova 42, Rijeka, Croatia.
Tamara BrautDepartment for Otolaryngology and Head and Neck surgery.ORCID 0000-0001-5828-9087
Marko VelepicDepartment for Otolaryngology and Head and Neck surgery.
S.P.E.C.I.E.S. · USUniversity of Rijeka · HR

Funding

Univeristy of Rijeka,Croatia grant number: uniri-biomed-18-121
6 · The paper itself

Abstract

abstractTo investigate whether laryngeal cancer cells express erythropoietin (Epo) and erythropoietin receptor (EpoR) and what is their possible relationship with clinical and pathological features of the tumor.We performed immunohistochemical analysis of Epo and EpoR expression on 78 tissue samples of invasive and in situ squamous cell laryngeal carcinoma.The statistical analysis showed a weak positive and statistically significant correlation of EpoHS and EpoR HS expression levels. Epo HS and EpoR HS levels did not correlate with patient sex or age, type of diagnosis, cancer stage, histological tumor grade, presence or absence of disease recurrence, type of oncologic cancer therapy provided, or results of selected laboratory blood work. The results show a statistically significant difference in Epo expression with respect to survival.We confirmed the presence of Epo an EpoR in malignant laryngeal tumors and demonstrated the correlation between Epo expression and survival. Further studies are needed to more precisely define the role of Epo and EpoR in treatment of patients with laryngeal cancer.

Indexed as

AgedAged, 80 and overErythropoietinFemaleHumansLaryngeal NeoplasmsMaleMiddle AgedReceptors, ErythropoietinROC CurveStatistics, NonparametricErythropoietinReceptors, Erythropoietin

Identifiers

PMID33545970
PMCPMC7837855
OpenAlexW3124233291

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.